Blackstone Life Sciences

In Q4 2018, Blackstone with assets under management of more than $500B announced the launch of Blackstone Life Sciences, a new business dedicated to investments in the life sciences, by reaching a definitive agreement to acquire Clarus Ventures, LLC, a leading global life sciences investment firm founded in 2005. Since inception, Clarus has raised $2.6 billion to invest Clarus I, II, III, IV and two side car vehicles. The co-founders of Clarus have worked together for over twenty years and led more than 75 investments. With offices in the world’s leading life sciences Research & Development hubs of Cambridge, Massachusetts and South San Francisco, the team is focused on funding pharmaceutical and biotechnology product investments through the late stages of clinical development and early commercialization, often in partnership with major and emerging biopharmaceutical companies.




Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life science sectors.

Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in 142 life science companies, leading to 64 IPOs and 40 mergers and acquisitions.